New drug alectinib outperforms standard therapy in asian lung cancer patients
NCT ID NCT02838420
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tested alectinib against crizotinib in 187 Asian patients with advanced ALK-positive non-small cell lung cancer who had not received prior treatment. Patients took either alectinib or crizotinib capsules twice daily. The study found that alectinib significantly improved progression-free survival compared to crizotinib, suggesting it may be a better first-line option for this population.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- alectinib (a targeted cancer drug taken as a capsule)
- What this could lead to
- If successful, alectinib could become a standard first treatment for Asian patients with ALK-positive lung cancer, offering better control of the disease.
- What could go wrong
- This trial is completed and showed positive results, but it only included Asian patients, so findings may not apply to other populations. Side effects like liver problems or lung inflammation are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC LYMPHOMA KINASE-POSITIVE NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
-
Beijing Cancer Hospital
Beijing, 100142, China
-
Beijing Chest Hospital
Beijing, 101149, China
-
Fudan University Shanghai Cancer Center
Shanghai, 200032, China
-
Guangdong General Hospital
Guangzhou, 510080, China
-
Harbin Medical University Cancer Hospital
Harbin, 150081, China
-
Jiangsu Cancer Hospital
Nanjing, 210009, China
-
Kangbuk Samsung Hospital
Seoul, 03181, South Korea
-
Rajavithi Hospital
Bangkok, 10400, Thailand
-
Ramathibodi Hospital
Bangkok, 10400, Thailand
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Shanghai chest hospital
Shanghai, 200030, China
-
Songklanagarind Hospital
Songkhla, 90110, Thailand
-
Sun Yet-sen University Cancer Center
Guangzhou, 510060, China
-
The First Affiliated Hospital of College of Medicine, Zhejiang University
Hangzhou, 310003, China
-
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, 510120, China
-
West China Hospital, Sichuan University
Chengdu, 610041, China
-
Zhejiang Cancer Hospital
Hangzhou, 310022, China
-
the First Hospital of Jilin University
Changchun, 130021, China